Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Cognitive Remediation Therapy Within a Secure Forensic Setting

24. července 2017 aktualizováno: Ken O'Reilly, Central Mental Hospital

Randomised Controlled Trial to Evaluate the Efficacy of Cognitive Remediation Within a Secure Forensic Setting for Schizophrenia Spectrum Patients

This clinical trial tests the feasibility, effectiveness and patient satisfaction with cognitive remediation therapy for patients diagnosed with schizophrenia or schizoaffective disorder within a forensic hospital. It is hypothesised that patients receiving cognitive remediation therapy will have an improvement in cognitive performance, real world functioning, symptoms, violence risk and benefit more from additional psychosocial treatment programmes over time relative to patients receiving treatment as usual. Furthermore it is hypothesised that it will be feasible to carry out such a study and that patients will report high rates of satisfaction with cognitive remediation therapy. Finally it is hypothesised that differences on the effectiveness measures will be maintained at 6 month follow up after the end of treatment.

Přehled studie

Detailní popis

This is a single centre randomised clinical trial to evaluate the feasibility, effectiveness and patient satisfaction with cognitive remediation therapy within a secure forensic setting for patients diagnosed with schizophrenia or schizoaffective disorder.

The feasibility of the intervention will be assessed using key indicators such as rate of enrolment, retention of patients in the trial, blinding effectiveness, and completion rate of the primary outcome measure. The effectiveness of the intervention will be assessed using the MATRICS consensus cognitive battery, symptoms (PANSS and CAINS) and real world functioning (SOFAS: Social and occupational functioning assessment scale). The effect of cognitive remediation on violence risk (HCR-20), programme completion and recovery (Dundrum 3 & 4) will also be examined, where programme completion is a measure of attainments from participating in additional psychosocial interventions and recovery is a measure of stability of mental state.

Patient satisfaction with cognitive remediation therapy will be assessed using a consumer constructed interview developed by Rose et al (2008) and administered by a social worker not involved in the delivery of cognitive remediation.

The trial will take place at the Republic of Ireland's Central Mental Hospital (CMH). The CMH is the only secure forensic psychiatric hospital for the Republic of Ireland, a population of 4.6 million. CMH provides specialised care for adults who have a mental disorder and are at risk of harming themselves or others.

After a baseline assessment to ensure eligibility and to obtain consent, an estimated 60 patients will be randomised to receive fourteen weeks of cognitive remediation versus treatment as usual. Patients who receive treatment as usual will be offered cognitive remediation upon completion of the study. Patients allocated to cognitive remediation will receive three individual sessions of cognitive remediation a week and one group session, fifty-six sessions in total The focus of the group session is to normalise cognitive difficulties that patients may be experiencing, to receive support and to help generalise gains. The primary outcome measure the MATRICS composite score and secondary outcome measures to assess real world functioning, symptoms, violence risk, programme completion and recovery will be administered at baseline, the end of treatment and at six month follow up. Secondary measures will also include feasibility outcomes and patient satisfaction with cognitive remediation therapy. All evaluators of the effectiveness measures will be blind to participant treatment condition at the time of assessment.

The cognitive remediation therapy is a principle driven intervention consisting of nine treatment principles: Principle 1 refers to relationship building, Principle 2 refers to collaborative goal setting, Principle 3 involves the session structure, Principle 4 concerns the content of the sessions, Principle 5, concerns the pacing of sessions, Principle 6 involves scaffolding and errorless learning, Principle 7 refers to meta-cognitive strategies, Principle 8 involves generalisation of gains, finally Principle 9 refers to managing ambivalence. The actual therapy will involve the use of a combination on pen, paper and computerised materials to stimulate patient's cognitive capacity and to provide them with the opportunity to apply meta-cognitive strategies.

The investigators hypothesise that it is feasible to carry out a randomised controlled trial within a single centre forensic setting and that patients will report high rates of satisfaction with cognitive remediation. It is also hypothesised that patients receiving cognitive remediation therapy will have an improvement in cognitive performance (the primary outcome measure), real world functioning, symptoms and violence risk over time relative to patients receiving treatment as usual; specifically that there will be a treatment by time interaction. Furthermore it is hypothesised that these differences will be maintained at six month follow up after the end of treatment.

In addition it is hypothesised that patients receiving cognitive remediation will show an improvement over time on the Dundrum programme completion and recovery scales compared to those receiving treatment as usual.

While meta-analytic reviews have demonstrated that cognitive remediation therapy has a beneficial effect on the cognitive deficits experienced by patients with schizophrenia (Wykes et al 2011), to the best of our knowledge there has been no study with forensic mental health patients. The current study will help answer whether it is feasible to deliver cognitive remediation within a forensic mental health setting and whether it is acceptable to patients. The study aims to contribute to the evidence base for psychological interventions within a forensic setting and to answer the question as to whether cognitive remediation has a beneficial effect and if it does whether this effect is maintained over time.

Typ studie

Intervenční

Zápis (Aktuální)

65

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Dublin, Irsko, D 14
        • Central Mental Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 65 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • A Structured Clinical Interview for Diagnostic and Statistical Manual IV (SCID) diagnosis of schizophrenia or schizoaffective disorder.

Exclusion Criteria:

  • Acutely psychotic, or judged too dangerous to participate in treatment, or being over 65 years of age.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Singl

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Cognitive Remediation Therapy
Principle driven cognitive remediation therapy, cognitive rehabilitation, cognitive training, cognitive enhancement.
Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
Ostatní jména:
  • Kognitivní trénink
  • Kognitivní vylepšení
  • Kognitivní rehabilitace
Aktivní komparátor: Treatment as Usual
Usual care.
Keep getting usual care.
Ostatní jména:
  • Standardní péče

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
The MATRICS Consensus Cognitive Battery (MCCB)
Časové okno: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Consensus neuropsychological assessment battery for cognitive deficits in schizophrenia
Group by time interaction: changes from baseline, to end of treatment (average 5 months)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Social and Occupational Functioning Assessment Scale (SOFAS)
Časové okno: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
100 item rating scale for measuring real world functioning independent of symptoms
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Positive and Negative Syndrome Scale (negative and disorganized factors)
Časové okno: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Rating scale for assessing psychiatric symptoms associated with schizophrenia
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Clinical Assessment Interview for Negative Symptoms (CAINS)
Časové okno: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Rating scale for assessing the negative symptoms of schizophrenia
Group by time interaction: changes from baseline, to end of treatment (average 5 months)

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Historical Clinical and Risk Management -20 (HCR-20)
Časové okno: Group by time interaction: changes from baseline, to 12 months
Rating scale for assessing violence risk
Group by time interaction: changes from baseline, to 12 months
Dundrum Toolkit: Programme Completion and Recovery Scales
Časové okno: Group by time interaction: changes from baseline to 12 months
Rating scale for assessing progress and recovery within a forensic mental health setting
Group by time interaction: changes from baseline to 12 months
Patient satisfaction.
Časové okno: Average 5 months.
Consumer developed interview exploring patient satisfaction with cognitive remediation.
Average 5 months.
Feasibility outcome: rate of enrolment.
Časové okno: 12 months.
Willingness of forensic mental health patients to participate in study.
12 months.
Feasibility outcome: rate of retention.
Časové okno: 12 months.
Number of patients who complete the intervention.
12 months.
Feasibility outcome: blinding.
Časové okno: 12 months.
Number of patients in which the blind is broken compared to number of patients in the study.
12 months.
Completion rate of primary outcome measures
Časové okno: 12 months.
Number of successfully completed primary outcome measures.
12 months.

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Ředitel studie: Professor Harry G Kennedy, M.D., Central Mental Hospital and Department of Psychiatry, Trinity College Dublin.
  • Ředitel studie: Professor Gary Donohoe, Ph.D., Department of Psychiatry, Trinity College Dublin.
  • Vrchní vyšetřovatel: Dr. Ken W O'Reilly, D.Psych.Sc., Central Mental Hospital and Department of Psychiatry, Trinity College Dublin.

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia

1. srpna 2014

Primární dokončení (Aktuální)

1. ledna 2017

Dokončení studie (Aktuální)

1. ledna 2017

Termíny zápisu do studia

První předloženo

4. února 2015

První předloženo, které splnilo kritéria kontroly kvality

10. února 2015

První zveřejněno (Odhad)

11. února 2015

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

25. července 2017

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

24. července 2017

Naposledy ověřeno

1. července 2017

Více informací

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit